After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA
Pfizer’s Xalkori has become a Phase III punching bag of sorts for top rivals in the cancer field. In June Novartis’ Zykadia picked up an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
